Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Novartis Group Stories

2013-08-21 16:25:57

- Novartis plans to ship a minimum of 30 million doses of its seasonal influenza vaccines to US customers for the 2013-2014 season CAMBRIDGE, Mass., Aug. 21, 2013 /PRNewswire/ -- Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4...

2013-08-01 20:21:18

- Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children[2,3] CAMBRIDGE, Mass., Aug. 1, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo(®) (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) to help prevent meningococcal disease caused by four strains of the bacterium Neisseria...

2013-06-03 12:28:53

- Investigational compound LDK378 is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC) EAST HANOVER, N.J., June 3, 2013 /PRNewswire/ -- Novartis today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated...

2013-06-02 08:20:17

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

2013-05-29 00:23:45

- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer EAST HANOVER, N.J., May 29, 2013 /PRNewswire/ -- Novartis will present new findings in the treatment of advanced cancers and other diseases with 170 abstracts at two prominent medical meetings. Research across the extensive Novartis product portfolio and pipeline showcases the progress in advancing care for patients with cancer and hematological diseases. Clinical data from multiple...

2013-04-25 12:27:39

-- Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria BASEL, Switzerland, April 25, 2013 /PRNewswire/ -- Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will support the...

2013-01-23 16:24:31

EAST HANOVER, N.J., January 23, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade(®) (deferasirox) for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration of at least 5 mg of iron per gram dry weight and a serum ferritin measurement greater than 300 micrograms per liter. Exjade is the first treatment...

2012-12-15 12:20:20

EAST HANOVER, N.J., Dec. 15, 2012 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor(®) (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative(3). Signifor is the first medicine to be approved in the US that addresses the underlying mechanism of Cushing's disease, a serious, debilitating endocrine disorder caused by the presence of a...

2012-12-14 20:21:08

EAST HANOVER, N.J., Dec. 14, 2012 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor(®) (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative(3). Signifor is the first medicine to be approved in the US that addresses the underlying mechanism of Cushing's disease, a serious, debilitating endocrine disorder caused by the presence of a...

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...